期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卵巢癌发病机制的研究进展 被引量：9

原文传递
导出
摘要 卵巢癌是妇科肿瘤中致死率最高的恶性肿瘤，探讨其发病机制一直是研究的热点，近年来基于临床病理学和分子遗传学方面的研究进展，提出了几种新的卵巢癌发生的模式，现对其进行综述。
作者 郭小荣 沈丹华 杜金荣
机构地区 北京大学人民医院病理科 哈尔滨医科大学第二医院病理科
出处 《中华病理学杂志》 CAS CSCD 北大核心 2008年第9期627-630,共4页 Chinese Journal of Pathology
关键词 发病机制 卵巢癌 分子遗传学 临床病理学 恶性肿瘤 妇科肿瘤 致死率 癌发生
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献28

  • 1Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 2004,164(5) :1511-1518.
  • 2Smith Sehdev AE, Sehdev PS, Kurman RJ,et al. Noinvasive and invasive micropapillary serous carcinoma of the ovary: a clinicopathological analysis of 135 cases. Am J Surg Pathol, 2003, 27(6) :725-736.
  • 3McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol, 2008,61 (2) : 152-163.
  • 4Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res, 1993,53 (7) : 1489-1492.
  • 5Shih IeM, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res, 2005,11 (20) :7273-7279.
  • 6Kumar R, Angelini S, Snellman E, et al. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol, 2004,122 (2) : 342-348.
  • 7Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature ,2002, 417(6892) :949-954.
  • 8Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatchrepair status. Nature,2002, 418(6901) :934.
  • 9Pohl G, Ho CL, Kurman RJ, et al. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res ,2005,65 ( 5 ) : 1994-2000.
  • 10Allen LF, Seboh-Leopold J, Meyer MB. CI-1040(PD184352), a targeted signal transduction inhibitor of MEK (MAPK). Semin Oncol,2003,30 (5 Suppl 16) : 105-116.

二级参考文献15

  • 1Shigemasa K, Tanimoto H, Parham GP, et al. Cyclin D1 overexpression and p.53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig, 1999, 6:102-108.
  • 2Worsley SD, Ponder BA, Davies BR.Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol, 1997, 64:187-188.
  • 3Seidman JD, Soslow RA, Vang R, et al.Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol, 2004, 35:918-933.
  • 4Tavassoli FA, Devilee P. WHO classification of tumours, pathology and genetics of tumours of the breast and female genital organs.Lyon: IARC Press,2003: 117-145.
  • 5Bourne TH, Whitehead MI, Campbell S, et al. Ultrasound screening for familial ovarian cancer. Gynecol Oncol, 1991, 43: 92-97.
  • 6Kennedy AW, Hart WR.Ovarian papillary serous tumors of low malignant potential ( serous borderline tumors ) . A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer, 1996, 78:278-286.
  • 7Singer G, Oldt R 3rd, Cohen Y, et aL Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Nad Cancer Inst, 2003, 95:484-486.
  • 8Shih IeM, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res, 2005, 11:7273-7279.
  • 9Worsley SD, Ponder BA, Davies BR.Overexpression of cyclin D1 in epithelial ovarian cancers.Gynecol Oncol, 1997,64:189-195.
  • 10Sui L, Tokuda M, Ohno M, et al. The concurrent expression of p27( kip1 ) and eyelin D1 in epithelial ovarian tumors. Gynecol Oncol, 1999, 73:202-209.

共引文献9

同被引文献127

  • 1张建民,回允中.妇产科病理学近十年的进展[J].中华病理学杂志,2005,34(10):619-622. 被引量：4
  • 2朱栋元,马廷行.p73基因研究进展[J].肿瘤防治杂志,2005,12(24):1909-1912. 被引量：2
  • 3杨蓉,冯捷,房祥忠,白符,成夜霞,刘晨,朱炜,李林.浆液性卵巢癌预后评分模型的建立和预后相关基因的筛选[J].中国妇产科临床杂志,2007,8(4):277-281. 被引量：5
  • 4王慧君,郑文新.Ⅱ型子宫内膜癌的前驱病变及其发生模式[J].中华病理学杂志,2007,36(8):505-507. 被引量：5
  • 5Bangson C, Rubins N, Glusman G, et al. The RUNX3 genesequence structure and regHlated expression [ J ]. Gene, 2001, 279 ( 2 ) : 221 - 232.
  • 6Ryu HS, Chang KH, Chang SJ, et al. Expression of TRAIL ( TNF - re- lated apoptosis - inducing ligand) receptors in cervical cancer [ J ]. J Gynecol Cancer, 2000, 10(2) :417 -424.
  • 7Levanon D, Negreanu V, Bemstein Y, et al. AML1, AML2 and AML3, the Human Member of the Runt Domain genefamily: cDNA Struc- ture, Expression and Chromosomal Localization [ J ]. Genomic, 1994, 23 (2) :425 -432.
  • 8Kim TY,Lee HJ, H wang KS, et 81. Methylation of RUNX3 in various types of human cancer and permaligant stages of gastric carcinoma[ J]. Lab Invest, 2004, 84(4) :479 -484.
  • 9Wei D, Gong W, Oh $C, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis [ J ]. Cancer Res, 2005, 65 ( 11 ) :4809 - 4816.
  • 10Ku JL, Kang SB, Shin YK, et al. Promoter hypennethylation downreg- ulates RUNX3 gene expression in colorectal cancer cell lines[ J]. Onco- gene, 2004, 23 (40) :6736 - 6742.

引证文献9

二级引证文献28

中华病理学杂志
2008年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部